Source-grounded facts extracted from Fulgent Genetics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Fulgent Genetics, Inc. shareholders approved Approval of the Company's 2026 Equity Incentive Plan. at the 2026-05-14 meeting.
“Proposal 4 Approval of the Company's 2026 Equity Incentive Plan. Votes For Votes Against Votes Abstained Broker Non-Vote 18,693,758 3,513,983 48,202 2,323,053”
Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. at the 2026-05-14 meeting.
“Proposal 3 Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Vote 19,800,226 2,410,239 45,478 2,323,053”
Fulgent Genetics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-14 meeting.
“Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Votes For Votes Against Votes Abstained Broker Non-Vote 24,470,414 87,192 21,390 —”
Fulgent Genetics, Inc. shareholders approved Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. at the 2026-05-14 meeting.
“Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Votes For Votes Withheld Broker Non-Vote Ming Hsieh 21,979,668 276,275 2,323,053 Linda Dong 16,836,781 5,419,162 2,323,053 Michael Nohaile, Ph.D. 17,258,629 4,997,314 2,323,053 Regina Groves 16,240,666 6,015,277 2,323,053”
Fulgent Genetics, Inc. reported first quarter ended March 31, 2026 results: revenue 71.1 million, net income -24.8 million, EPS -0.80. Guidance reaffirmed.
“for fiscal year 2026 • Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash • Revenue of $71.1 million • GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% • GAAP loss of $24.8 million, or”
Fulgent Genetics, Inc. completed an acquisition involving Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting (closed 2026-03-17).
“On March 17, 2026, the transactions contemplated by the APA were completed (the "APA Closing").”
Fulgent Genetics, Inc. completed an acquisition involving Inform Diagnostics, Inc. (closed 2026-03-17).
“On March 17, 2026, the transactions contemplated by the PSA were completed (the "PSA Closing").”
Fulgent Genetics, Inc. entered into Asset Purchase Agreement with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting, LLC valued at $43.0 million in cash (effective 2025-12-20).
“On December 20, 2025, Buyer entered into an Asset Purchase Agreement (the “APA”) with Bako Pathology LP (“Sellers’ Representative”), Bako Pathology Holdings Corp., BPA Holding Corp., Bakotic Pathology Associates, L.L.C., Podceuticals L.L.C., GBRL Consulting, LLC (collectively with Sellers’ Representative, the “Sellers”), and Fulgent Therapeutics, LLC (solely for purposes of Section 11.16 (and Article XI as it relates to Section 11.16) of the APA), pursuant to which Sellers, among other things, agreed to sell and Buyer agreed to purchase and assume, substantially all of the assets and certain specified liabilities related to Sellers’ business in dermatopathology and podiatric pathology and molecular diagnostic services and therapeutic products, for a base purchase price of $43.0 million in cash, subject to certain customary price adjustments.”
Fulgent Genetics, Inc. entered into Purchase and Sale Agreement with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp. valued at $12.5 million in cash (effective 2025-12-20).
“On December 20, 2025, Inform Diagnostics, Inc. (the “Buyer”), a wholly owned subsidiary of Fulgent Genetics, Inc. (the “Company”), entered into a Purchase and Sale Agreement (the “PSA”) with Bako Pathology LP, Bako Pathology Holdings Corp., BPA Holding Corp. (the “Seller”), Dermatopathology Experts, LLC (the “Target”), and Fulgent Therapeutics, LLC (solely for purposes of Section 11.16 (and Article XI as it relates to Section 11.16) of the PSA), pursuant to which Seller, among other things, agreed to sell and Buyer agreed to purchase, all of the issued and outstanding equity interests of the Target, for a base purchase price of $12.5 million in cash, subject to certain customary price adjustments.”
Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, the compensation of the Company's named executive officers at the 2024-05-16 meeting.
“Proposal 3 Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officers. Votes For Votes Against Votes Abstained Broker Non-Vote 19,786,239 573,411 25,950 4,095,268”
Fulgent Genetics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-16 meeting.
“Proposal 2 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. Votes For Votes Against Votes Abstained Broker Non-Vote 24,238,701 222,804 19,363 —”
Fulgent Genetics, Inc. shareholders approved Election of directors at the 2024-05-16 meeting.
“Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2025 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified. Votes For Votes Withheld Broker Non-Vote Ming Hsieh 20,071,185 314,415 4,095,268 Michael Nohaile, Ph.D. 17,462,830 2,922,770 4,095,268 Regina Groves 17,487,701 2,897,899 4,095,268 Linda Marsh 15,854,682 4,530,918 4,095,268”
Fulgent Genetics, Inc. reported first quarter ended March 31, 2024 results: revenue $64.5 million, net income loss of $13.5 million, EPS $0.45 per share. Guidance reaffirmed.
“Fulgent Reports First Quarter 2024 Financial Results • Total Revenue of $64.5 million • Core Revenue grows 1% year-over-year to $63.2 million • Reiterates Full Year 2024 Core Revenue Guidance of $280 million”
Fulgent Genetics, Inc. reported fiscal quarter and year ended December 31, 2023 results: revenue Total Revenue of $289.2 million, net income GAAP loss of $167.8 million, EPS $5.63 per share.
“Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results • Full Year 2023 Total Revenue of $289.2 million”
Fulgent Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue Total Revenue of $85 million, net income GAAP loss of $13.1 million, or $0.44 per share, EPS GAAP loss of $13.1 million, or $0.44 per share. Guidance reaffirmed.
“Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023. Third Quarter 2023 Results: • Total Revenue of $85 million • Core Revenue 1 grew 17% year-over-year to $66 million • GAAP loss of $13.1 million, or $0.44 per share • Non-GAAP loss of $11.7 million, or $0.39 per share • Adjusted EBITDA of $18.1 million • Generated cash flow from operations of $10.2 million • Cash, cash equivalents, and investments in marketable securities of $851 million as of September 30, 2023”
Fulgent Genetics, Inc. reported second quarter ended June 30, 2023 results: revenue $68 million, net income GAAP loss of $11.2 million, or $0.38 per share, EPS $0.38 per share. Guidance raised.
“X-99.1 Exhibit 99.1 Fulgent Reports Second Quarter 2023 Financial Results • Total Revenue of $68 million • Record Core Revenue of $67 million, growth of 48% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $260 million and Narrows Expected Loss EL MONTE, CA, August 4, 2023 — Fulgent Genetics, Inc.”
Fulgent Genetics, Inc. shareholders approved Approval of an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares at the 2023-05-18 meeting.
“Proposal 4 Approval of an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares.”
Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, the compensation of our named executive officers at the 2023-05-18 meeting.
“Proposal 3 Approval, on a non-binding advisory basis, the compensation of our named executive officers.”
Fulgent Genetics, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-18 meeting.
“Proposal 2 Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.”
Fulgent Genetics, Inc. shareholders approved Election of directors at the 2023-05-18 meeting.
“Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2024 Annual Meeting and until his or her successor is duly elected and qualified.”
Fulgent Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue $66.2 million, net income $15.3 million, EPS $0.52 per share. Guidance raised.
“Total Revenue of $66.2 million • Record Core Revenue of $62.7 million, growth of 150% year-over-year • Raises Full Year 2023 Core Revenue Guidance to $250 million”
Fulgent Genetics, Inc. reported the fiscal quarter and year ended December 31, 2022 results: revenue $619.0 million, net income GAAP income of $143.4 million, EPS $4.63 per share.
“Current Report on Form 8-K. --- EX-99 (EX-99.1) --- EX-99 Exhibit 99.1 Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results • Full Year 2022 Total Revenue of $619.0 million; Q4 Total Revenue of $67.7 million • Full Year 2022 Core Revenue grows 95% year-over-year to $181.5 million; Q4 Core Revenue grows 97% year-over-year to $55.0 million TEMPLE”
Fulgent Genetics, Inc. amended Lease Amendment (effective 2023-01-06).
“On January 6, 2023, Fulgent Therapeutics LLC, a subsidiary of Fulgent Genetics, Inc. (the “Company”), amended its existing office lease agreement for the Company’s headquarters at 4978 Santa Anita Avenue, Temple City, California 91780 (the “Lease Amendment”).”
Regina Groves was appointed as Director at Fulgent Genetics, Inc..
“On January 3, 2023, the Board of Directors (the “Board”) of the Fulgent Genetics, Inc. (the “Company”) appointed Ms. Regina (“Reggie”) Groves to serve as a member of the Board.”
Fulgent Genetics, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605).
“November 18, 2022, Fulgent Genetics, Inc. (the “Company”) received a letter (the “Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was no longer in compliance with the audit committee requirements as set forth in Nasdaq Listing Rule 5605, which requires the Audit Committee of the Board of Directors of the Company (the “Audit Committee”) to be comprised of a minimum of three independent directors. The Audit Committee is currently comprised of two independent directors and one vacancy. The Letter provides that the Company is eligible for a cure period in which to”
Fulgent Genetics, Inc. reported third quarter ended September 30, 2022 results: revenue $105.7 million, net income $1.7 million, EPS $0.06 per share.
“Exhibit 99.1 to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Fulgent Genetics Reports Third Quarter 2022 Financial Results • Revenue totals $105.7 million • Core Revenue grows 110% year-over-year to $56.0 million TEMPLE CITY, CA, November 7, 2022 —Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent”, or the”
Leonard Post resigned as Director and Chair of the Nominating and Corporate Governance Committee at Fulgent Genetics, Inc..
“On October 31, 2022, Leonard Post notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board and as the Chair of the Nominating and Corporate Governance Committee of the Board effective as of October 31, 2022.”
John Bolger resigned as Director at Fulgent Genetics, Inc..
“On September 24, 2022, John Bolger notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board.”
Yun Yen resigned as Director at Fulgent Genetics, Inc..
“On June 25, 2022, Yun Yen, M.D., Ph.D., F.A.C.P., notified the Board of Directors (the “Board”) of Fulgent Genetics, Inc. (the “Company”) of his decision to resign from the Board, the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee of the Board, effective as of June 25, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.